• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up2.00% Nasdaq Up1.66%

    Alnylam Pharmaceuticals, Inc. (ALNY)

    -NasdaqGS
    59.55 Up 2.59(4.55%) Feb 12, 3:59PM EST
    |After Hours : 59.00 Down 0.55 (0.92%) Feb 12, 4:43PM EST
    ProfileGet Profile for:
    Alnylam Pharmaceuticals, Inc.
    300 Third Street
    3rd Floor
    Cambridge, MA 02142
    United States - Map
    Phone: 617-551-8200
    Fax: 617-551-8101
    Website: http://www.alnylam.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:N/A

    Business Summary 

    Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company’s clinical development programs include Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin amyloidosis (ATTR); ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; Fitusiran, an investigational RNAi therapeutic that is in Phase I clinical trial for the treatment of hemophilia and rare bleeding disorders; ALN-CC5, which is in Phase I/II clinical trial for the treatment of complement-mediated diseases; and ALN-AS1 for the treatment of hepatic porphyrias. Its product development programs also include ALN-AAT for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; ALN-PCSsc that is in Phase I clinical trial for hypercholesterolemia; ALN-HBV for the treatment of Hepatitis B virus; ALN-AC3 for the treatment of hypertriglyceridemia; ANGPTL3 for the treatment of hypertriglyceridemia and mixed hyperlipidemia; ALN-AGT for the treatment of hypertensive disorders of pregnancy, including preeclampsia; ALN-GO1 for the treatment of primary hyperoxaluria type 1; ALN-HDV for the treatment of HDV infection; and ALN-PDL for the treatment of chronic liver infections. The company has strategic alliances and collaboration agreements with Ionis Pharmaceuticals, Inc.; Novartis Pharma AG; Novartis/Arrowhead; F. Hoffmann-La Roche Ltd; Roche/Arrowhead; Takeda Pharmaceutical Company Limited; Kyowa Hakko Kirin Co., Ltd.; Cubist Pharmaceuticals, Inc.; Ascletis BioScience Co., Ltd.; Monsanto Company; Sanofi Genzyme; The Medicines Company; Arbutus Biopharma Corporation; Protiva Biotherapeutics, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Alnylam Pharmaceuticals, Inc.

    Corporate Governance 
    Alnylam Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Feb 1, 2016 is 6. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 5; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. John M. Maraganore M.D., Ph.D., 53
    Chief Exec. Officer and Exec. Director
    1.14M25.28M
    Mr. Barry E. Greene , 53
    Pres and Chief Operating Officer
    798.00K5.28M
    Mr. John K. Clarke , 62
    Founder, Director and Chairman of Nominating & Corp. Governance Committee
    60.00KN/A
    Mr. Michael P. Mason , 41
    VP of Fin. and Treasurer
    345.00K1.77M
    Ms. Laurie Bartlett Keating , 62
    Sr. VP, Gen. Counsel and Sec.
    269.00K0.00
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders